The largest database of trusted experimental protocols

Berzosertib

Manufactured by MedChemExpress
Sourced in United States

Berzosertib is a small molecule inhibitor that targets the ATR (Ataxia Telangiectasia and Rad3-related) kinase. ATR is a key regulator of the cellular response to DNA damage and replication stress. Berzosertib functions by inhibiting the ATR kinase activity, thereby disrupting the ATR-mediated DNA damage response pathway.

Automatically generated - may contain errors

3 protocols using berzosertib

1

Quantifying Viable Tumor Cells by MTT Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
MTT analysis was performed to quantify viable tumor cells in culture and to determine IC50 values after treatment with Adavivint, Alisertib, Berzosertib, Olaparib and Trametinib (all obtained from MedChemExpress, New York, USA). For dose response analyses, cells were seeded in a 96-well plate under standard culture conditions. After overnight culture, the cells were treated with a dilution series of the various inhibitors. 48 h after the initial treatment, all inhibitors were replenished and after 120 h MTT (5 mg/ml) was added to each well, followed by an incubation for 90 min at 37 °C. Subsequently, supernatants were aspirated, and precipitated formazan dye was solubilized with DMSO. Absorbance was measured at 540 nm using a Tecan infinite F50 spectrophotometer and viable tumor cells were calculated by the mean absorbance relative to DMSO control.
+ Open protocol
+ Expand
2

Drug Combination Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
5-fluorouracil (5-FU; S1209), oxaliplatin (S1224), SN-38 (S4908), and olaparib (AZD2281, Ku-0059436, S1060) were purchased from Selleckchem. Berzosertib (ATRi; HY-13902), ceralasertib (ATRi; HY-19323), rabusertib [CHK1 inhibitor (CHKi); HY-14720], adavosertib [Wee1 inhibitor (Wee1i); HY-10993], AZD0156 [ATM inhibitor (ATMi); HY-100016], and nedisertib [DNA-PK inhibitor (DNA-PKi); HY-101570] were purchased from MedChemExpress, while MG-132 (474790) was purchased from Merck and hydroxyurea (HU; H8627) from Sigma.
+ Open protocol
+ Expand
3

Drug Combination Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
5-fluorouracil (5-FU; S1209), oxaliplatin (S1224), SN-38 (S4908), and olaparib (AZD2281, Ku-0059436, S1060) were purchased from Selleckchem. Berzosertib (ATRi; HY-13902), ceralasertib (ATRi; HY-19323), rabusertib [CHK1 inhibitor (CHKi); HY-14720], adavosertib [Wee1 inhibitor (Wee1i); HY-10993], AZD0156 [ATM inhibitor (ATMi); HY-100016], and nedisertib [DNA-PK inhibitor (DNA-PKi); HY-101570] were purchased from MedChemExpress, while MG-132 (474790) was purchased from Merck and hydroxyurea (HU; H8627) from Sigma.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!